Three domestic reforms are pushing Korea from the back of the launch queue to the front.
For global pharmaceutical companies, South Korea has long been a paradox: clinically sophisticated, fast-growing, and yet often deprioritized in global launch sequencing.
Three structural barriers drove this dynamic. First, reimbursement timelines were exceptionally long. Second, conservative cost-effectiveness requirements resulted in low reimbursement prices that discouraged commercialization of high-cost therapies. Third, those relatively low prices were publicly disclosed, creating potential exposure through international reference pricing (IRP) systems in other markets. Together, these barriers often led manufacturers to delay launches in Korea despite the market’s underlying attractiveness.
That dynamic is now beginning to change. A sweeping reform package announced by Korea’s Ministry of Health and Welfare (MoHW) directly targets all three pain points. At the same time, the US Most-Favored-Nation (MFN) drug pricing policy has elevated Korea’s strategic weight in global pricing decisions. These developments make Korea a market that global pharma can no longer afford to manage as an afterthought.
A market that already deserves attention
Korea’s pharmaceutical market was valued at approximately USD 29.2 billion in 2025, projected to reach USD 53.9 billion by 2032 at a CAGR of 9.17%, making it the third largest in Asia-Pacific after China and Japan. Demographic trends further enhance its strategic importance: Korea became a "super-aged" society in 2024, with more than 20% of its population aged 65 or older. By 2050, that figure is projected to exceed 40%, driving sustained demand for innovative therapies across oncology, neurology, cardiovascular disease, metabolic disease, immunology, and other age-related conditions.
Korea’s clinical research ecosystem is equally impressive. Seoul ranked first globally among cities in clinical trial density for seven consecutive years from 2017 to 2023, while Korea accounted for 3.46% of all global clinical trials in 2024, ranking sixth worldwide. These strengths have made Korea one of the world's leading destinations for clinical development and real-world evidence (RWE) generation.
Yet these have had limited impact on launch priority. The barriers were not about market attractiveness, but pricing and market access friction that often discouraged early launches. The reforms described below are now beginning to change that.
Three policy reforms that could reshape Korea’s role in launch sequencing
Reform 1: Flexible contract system
Timeline: Implemented June 2026
Korea’s core dilemma has been structural: rigorous health technology assessment (HTA) requirements produce low reimbursement prices that are publicly disclosed and picked up by IRP systems in other countries. The flexible contract system addresses this issue by expanding a broader dual-pricing framework beyond the limited Risk Sharing Agreement (RSA) context, where confidential net price arrangements were primarily applied to therapies for severe or life-threatening diseases with limited treatment alternatives. Under the new system, the publicly visible list price can be set up to the highest level permitted within the A8 reference-country range (US, UK, Germany, France, Italy, Switzerland, Japan, Canada), while the actual reimbursed price is negotiated confidentially with National Health Insurance Service (NHIS). This mechanism now applies systematically across a wider range of products and lifecycle stages, including, but not limited to, new drug listings, indication expansions, already-listed products, and biosimilars. Patients are charged based on the confidentially agreed net price, avoiding the patient refund process that had created operational burden under traditional RSA models.
An important external consideration is the emerging US MFN framework. Korea is included in the 19-country reference basket proposed under both the GLOBE (Part B) and GUARD (Part D) models. Given Korea’s relatively low NHIS prices, Korean prices could exert downward pressure on future US MFN benchmarks. The flexible contract system could help provide a potential safeguard by separating publicly visible list prices from confidential net prices. As the proposed MFN framework evolves, the system could play an increasingly important role in managing international pricing exposure.
Reform 2: Fast-track reimbursement for rare and innovative drugs
Timeline: Pilot H2 2026 → Implementation 2027 → Expand to innovative drugs 2028
Another longstanding challenge has been the time required to secure reimbursement. Although Korea’s formal review period is 240 days, actual timelines are often much longer, with some rare disease therapies taking longer than three years to progress from regulatory approval to reimbursement. One contributor is the sequential nature of the process: Health Insurance Review and Assessment Service (HIRA) clinical assessment, NHIS price negotiation, and MoHW approval occur consecutively, compounding delays at every stage. In addition, reimbursement submissions undergo extensive clinical and economic scrutiny, frequently resulting in iterative evidence review and prolonged negotiations. For rare diseases, the process is further complicated by the challenges of applying conventional Incremental Cost-Effectiveness Ratio (ICER) methodologies to assess treatment value.
Policymakers are now considering a markedly different approach. Under a “reimburse first, then evaluate” paradigm, rare disease treatments target reimbursement within 100 days. HIRA and NHIS aim to review simultaneously, sharing information in real time and eliminating inter-agency delays. HTA assessments at listing may also be streamlined, with international price benchmarks used in place of full economic modeling, while formal price reassessment would occur post-listing using RWE. To support this shift, the government is exploring an AI-enabled digital infrastructure to accelerate drug evaluation and reimbursement review.
The government also intends to expand this approach beyond rare disease therapies to selected innovative medicines from 2028. This marks a significant departure from Korea’s traditional front-loaded evaluation model and reinforces a broader shift toward rewarding innovation and accelerating patient access.
Reform 3: Weighted ICER thresholds
Timeline: Implementation 2027
Korea’s low ICER threshold has been a critical barrier, often contributing to lengthy reimbursement negotiations and constrained reimbursement prices. The unofficial threshold is generally understood to be up to KRW 25 million per QALY (~ USD 17,000) for standard therapies and up to KRW 50 million (~ USD 33,000) for oncology and rare disease treatments. These benchmarks have remained effectively unchanged since the introduction of Korea’s pharmacoeconomic evaluation system in 2006 and are widely viewed as conservative compared with those applied in other HTA markets.
The government is now moving toward a more structured and flexible approach. Rather than relying only on a conventional ICER framework, the reform direction would allow value assessment to more explicitly consider factors such as disease severity, clinical benefit, and budget impact. MoHW has described this as part of a broader effort to modernize cost-effectiveness evaluation and better reflect the value of innovative medicines. Recent reimbursement decisions already point in this direction: Imfinzi in Biliary Tract Cancer (BTC) and Trodelvy in Triple-Negative Breast Cancer (TNBC) were approved under flexible ICER criteria despite exceeding traditional acceptance ranges.
The forthcoming reform formalizes this trend. Upon implementation, the reform would provide a more transparent and predictable route to reimbursement for innovative oncology and rare disease medicines, while allowing broader value considerations to be reflected in pricing decisions.
What this means for global pharma
Greater pricing flexibility could support reassessment of Korea launch sequencing
The flexible contract system may give manufacturers greater flexibility to pursue globally defensible list prices in Korea, while potentially reducing the IRP spillover risk that historically contributed to delayed launches. Combined with its potential to help mitigate future MFN reference risk, this may reduce the need to deprioritize Korea solely to protect global pricing architecture. Manufacturers should reassess Korea’s role in global launch sequencing, particularly for high-cost therapies where IRP concerns have been the primary barrier to early market entry.
As Korea opens to innovation, first movers will set precedent
Fast-track reimbursement, weighted ICER, and post-market evaluation together create a more favorable environment for innovative medicines targeting high unmet need. Companies with upcoming launches in oncology, rare disease, and neurology should factor this shift into their launch timing now. Early entrants will be best positioned to establish pricing precedents and build relationships with key stakeholders before the pathway becomes more widely utilized.
Evidence generation must be built in from day one
Under a “reimburse first, then evaluate” approach, reimbursement would no longer mark the end of the market access process but the beginning of an ongoing evidence and pricing dialogue with HIRA, NHIS, and MoHW. With future price reassessments expected to rely increasingly on RWE, manufacturers will need robust Korea-specific data strategies from the outset. Real-world data collection should be incorporated into clinical development and launch planning early rather than added after reimbursement has been secured.
Why local Korea expertise matters more than ever
These reforms add new layers of complexity that make Korea-specific pricing expertise more valuable and harder to substitute with generic global frameworks.
The dual price structure makes net price assessment critical
Under the flexible contract system, publicly disclosed list prices no longer reflect actual transaction prices, so conventional pricing research increasingly misses Korea’s real pricing landscape. Understanding true net price range requires triangulation through primary research, including interviews with key stakeholders and market access experts with the latest insights. In addition, accurately assessing the dual price structure requires insight into its interaction with RSA and other post-listing price management mechanisms, making specialized pricing and market access (P&MA) expertise essential for any Korea pricing engagement.
Policy ambiguity requires real-time local interpretation
Many of these reforms remain under development: operational details and eligibility criteria of the flexible contract system are still being defined, weighted ICER criteria have yet to be finalized, and the implications for existing post-listing price management mechanisms and RWE requirement remain uncertain. Organizations relying solely on published policy documents risk working from incomplete or outdated information. Keeping pace requires continuous monitoring of MoHW announcements, HIRA consultations, NHIS guidance, and broader stakeholder sentiment. This is where local expertise becomes critical, translating evolving policy signals into actionable implications before they are formalized.
A market at a turning point
The structural barriers that historically led manufacturers to deprioritize Korea (slow access, low prices, transparent pricing) are being directly addressed. The reforms of 2026–2028 represent a meaningful change in how innovative therapies are assessed, priced, and reimbursed in one of Asia-Pacific’s largest pharmaceutical markets.
Korea’s growing role in global pricing dynamics, through IRP and potentially through MFN-style frameworks, means decisions made in Seoul could have implications extending far beyond Korea itself. Success will depend not only on understanding the direction of reform, but also on anticipating how evolving policies are implemented in practice. Companies that engage early and build Korea-specific market access strategies today will be best positioned to capitalize on the opportunities emerging tomorrow.
If you would like to discuss how these developments may affect your portfolio, launch plans, or pricing strategy, our team would be pleased to share our perspectives and support your assessment.
